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Background: A novel classification of pulmonary adenocarcinoma 
(ADC) distinguishing five growth patterns has been established by 
the International Association for the Study of Lung Cancer/American 
Thoracic Society/European Respiratory Society. There is evidence 
that an additional cribriform pattern associates with a distinct clini-
cal behavior.
Methods: We evaluated the predominant growth pattern of 674 
resected ADC as recommended by the International Association for 
the Study of Lung Cancer/American Thoracic Society/European 
Respiratory Society, including the cribriform pattern. The predomi-
nant pattern type was correlated with clinical, molecular, and sur-
vival data.
Results: Two hundred forty-eight (36.8%) of the pulmonary ADC 
were solid, 207 (30.6%) were acinar, 101 (15%) were papillary, 55 
(8.2%) were micropapillary, 35 (5.2%) were lepidic, and 28 cases 
(4.2%) were cribriform predominant (cpADC). Minor cribriform 
components were frequently observed (28.6% of all cases). cpADC 
showed the second highest proliferative capacity of all patterns, 
no somatic mutations in the epidermal growth factor receptor (p = 
0.001) and a high rate of KRAS mutations. Overall survival (OS) of 
patients with cpADC (mean OS: 62.7 months) ranged in between 
survival times of patients with acinar (mean OS: 71.3 months) and 
solid predominant ADC (mean OS: 54.5 months); cpADC was asso-
ciated with the worst disease-free survival (DFS) of all patterns 
(mean DFS: 36.9 months). Both associations were confirmed by 
multivariate analysis (p < 0.01 for both OS and DFS). Hazard ratios 
for cpADC were 1.72 for OS and 2.99 for DFS, with lepidic predomi-
nant ADC set as reference (hazard ratio: 1).
Conclusions: Our data support the introduction of cpADC as a novel 
category into future morphology based on pulmonary ADC classi-
fications. Further international studies are required to validate the 
reported clinicopathological associations of the cribriform pattern.
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(J Thorac Oncol. 2015;10: 638–644)
On the basis of significant novel developments in the field of diagnostic, prognostic, and predictive parameters in 
pulmonary adenocarcinomas (ADC) over the past decade 
aided by a translation of these findings into the clinical setting, 
a novel multidisciplinary classification of pulmonary ADC 
was published in 2011 by the International Association for 
the Study of Lung Cancer (IASLC), the American Thoracic 
Society (ATS), and the European Respiratory Society (ERS).1 
This classification is based on a semiquantitative assessment 
of specific histomorphological growth patterns of invasive 
ADC in 5% increments with an ultimate classification of each 
case as lepidic, acinar, papillary, micropapillary, or solid pre-
dominant ADC. The prognostic value and the reproducibility 
of this classification have been validated in multiple studies 
worldwide.2–9
Beyond these five predefined and well-established his-
tomorphological patterns, there is growing evidence that addi-
tional morphological growth patterns might exist that show 
distinct clinical associations. Of these, the so-called cribri-
form pattern is currently the most prominent. With respect 
to histomorphology, the cribriform pattern might be placed 
somewhere in between the acinar and solid pattern; however, 
first data indicate that patients with cribriform tumors have 
a relatively poor outcome comparable with the outcome of 
patients with other ADC.10,11
To further dissect the prognostic relevance of the crib-
riform pattern of ADC and its association with clinicopatho-
logical characteristics, we analyzed a series of 674 surgically 
resected ADC cases with available clinicopathological data 
including overall survival (OS) and disease-free survival (DFS).
PATIENTS AND METHODS
Patients and Methods
We retrospectively screened our archives from 2002 
to 2010 for all completely resected invasive ADC with fully 
available slide material and clinicopathologic data on sex, 
age, tumor size, lymph node and distant metastases, type 
of resection, and survival. All tumors were resected in the 
Thoraxklinik at Heidelberg University, Germany. Diagnoses 
were made according to the criteria of the current World 
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Health Organization classification for lung cancer.12 For tumor 
staging, the seventh Edition of the Union for International 
Cancer Control/American Joint Committee on Cancer tumor, 
node, metastasis classification13 was applied to all cases.
Histological Evaluation
All specimens were formalin fixed immediately after 
resection and stained with hematoxylin and eosin (H&E). In 
addition, mucin stains (Periodic acid-Schiff with diastase) 
were performed from representative slides of each specimen. 
All slides were reviewed by A.W. and W.W. All available slides 
for every case were analyzed, and the exact number of reviewed 
tumor bearing slides was not specifically documented per 
case. However, from a previous study,7 we know that the mean 
number of tumor bearing slides in randomly selected cases 
from our archives is four (range 1–12). To focus on our main 
question and to exclude possible confounders, only cases with 
pure invasive ADC were included in the cohort. Histological 
classification was done according to the criteria of the IASLC/
ATS/ERS classification,1 recording the percentage of each 
established histological component (lepidic, acinar, papil-
lary, micropapillary, and solid) and the cribriform pattern in 
5% increments. The pattern with the highest percentage was 
designated as the predominant pattern; all other patterns (e.g., 
secondary or tertiary) are further referred to as minor pat-
tern. A cribriform pattern was diagnosed in accordance with 
Kadota et al11 when nests of neoplastic cells with back-to-back 
fused, poorly formed glandular spaces and lacking intervening 
stroma or invasive tumor nests that produce glandular lumina 
without solid components were present (Fig. 1). Four hundred 
seventy-one cases of our 674 cases were already part of a pre-
vious study.6 However, to evaluate the presence/absence of the 
cribriform pattern in those cases and to avoid a bias in pattern 
designation, all cases were evaluated completely de novo with 
respect to overall pattern distribution within the course of the 
present study.
Immunohistochemistry and Mutation Analyses
Expression of the diagnostic markers thyroid transcrip-
tion factor-1 (TTF-1), napsin and cytokeratin 7 (CK7),14 the 
proliferation index (Ki-67),15 and mutations of KRAS, EGFR, 
BRAF,16 or translocations of ALK and ROS116,17 were analyzed 
as described previously in detail.
Statistics
Differences in percentages of cribriform growth between 
the predominant pattern types and differences in proliferative 
capacity for the respective predominant patterns were calcu-
lated with analysis of variance. Associations with clinicopatho-
logical parameters, immunohistochemical data, and molecular 
data were calculated with χ2 test and χ2 test for trends. Survival 
probabilities were plotted with the Kaplan-Meier method; a 
log-rank test was used to probe for the significance of differ-
ences in survival probabilities. Multivariate survival analysis 
was performed with the Cox proportional hazard model.
RESULTS
Cohort
The pulmonary ADC cohort consisted of 674 cases. 
Fourteen patients (2.1%) received wedge resection, 8 patients 
(1.2%) segmentectomy, 549 patients lobectomy (81.5%), 16 
patients bilobectomy (2.4%), and 87 patients pneumonec-
tomy (12.8%), accompanied by systematic lymph node dis-
section in the vast majority of the cases. Stage distribution 
of the analyzed cases was as follows (n): stage I (264), stage 
II (145), stage III (243), and stage IV (22). Patients with 
stage IV disease are mostly a consequence of the applied re-
staging from the sixth to the seventh edition of the tumor, 
node, metastasis classification. In addition, some patients had 
oligometastatic disease (brain metastasis) and were treated 
with surgical resection in a curative intent in accordance 
with the national guidelines. In these patients, individualized 
FIGURE 1.  Histomorphological 
examples for cribriform growth. 
Overview (A) and details (B–D) of 
the cribriform pattern as analyzed 
in this study.
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therapeutic strategies were applied after interdisciplinary dis-
cussions. The respective metastases were surgically resected 
or treated with definite radiotherapy. None of the patients was 
treated with neoadjuvant radio- and/or chemotherapy. Three 
hundred ninety-two (58.2%) patients were male, and 282 
(41.8%) were female. Mean age at diagnosis was 62.6 years. 
One hundred ninety-seven (29.2%) patients received adju-
vant chemotherapy following the guidelines in effect at the 
time of diagnosis, 123 (18.2%) received adjuvant mediastinal 
radiation. Two hundred thirty-nine (35.5%) patients died dur-
ing follow-up, 271 (40.2%) relapsed. Mean follow-up time of 
patients alive at the end point of analysis was 38.2 months, 
and mean follow-up time of patients without recurrence at 
the end point of analysis was 33.0 months. For 357 of our 
674 cases (53.0%), data on smoking habits were available. 
The distribution of important clinicopathological variables is 
provided in Table 1.
Distribution of the Cribriform Pattern
With respect to the predominant growth pattern, we 
found 248 (36.8%) of our cases to be solid, 207 (30.6%) to be 
acinar, 101 (15%) to be papillary, 55 (8.2%) to be micropapil-
lary, 35 (5.2%) to be lepidic, and 28 cases (4.2%) to be cribri-
form. In addition, another 193 cases (28.6%) had a cribriform 
component not representing the predominant pattern (minor 
pattern). In cases with a minor cribriform growth pattern, the 
median percentage of this pattern among all growth patterns 
was 15%. The frequency of a minor cribriform component 
was highest in solid predominant ADC (90 of 248; 36.3%), 
followed by acinar predominant ADC (55 of 207, 26.6%) and 
was only infrequently or not at all observed in papillary (12 of 
101, 11.9%), micropapillary (8 of 55, 14.5%), and lepidic (0 
of 35, 0%) predominant ADC (p < 0.001; Fig. 2).
In 21 of the cases now classified as predominantly crib-
riform, data on our previous analysis of pattern distribution 
were available6 and could be compared. By doing so, we found 
that 15 (71.4%) of the cases now designated as being cribri-
form predominant formerly were classified as acinar predomi-
nant and 6 cases were initially classified as solid predominant 
(28.6%). When percentages of cribriform growth were strictly 
included as acinar growth as recommended by the IASLC/
ATS/ERS classification,1 all cribriform cases fell in the cat-
egory of acinar predominant ADC.
The Cribriform Pattern—Clinical 
and Pathological Correlations
Although nodal positive and high-stage tumors showed 
a slight trend toward a higher fraction of cribriform pre-
dominant cases, none of the clinicopathological variables 
investigated was significantly associated with cribriform pre-
dominant growth (Table 1). An association with smoking pat-
terns was not evident.
In 626 of our 674 cases, we had data on proliferative 
activity (Ki-67) from a previous study.15 In the current data set, 
we could confirm the previously reported highly significant 
association of patterns with proliferative activity. We found 
the cribriform pattern as the pattern with the second highest 
proliferative activity (mean 32.6%), ranging in between the 
mean proliferative activity of acinar (23.3%) and solid pre-
dominant (37.5%) ADC (Fig. 2).
The Cribriform Pattern—Correlations with 
the Immunophenotype and Molecular Data
Comparing cribriform predominant ADC (cpADC) and 
non-cpADC and ADC with a cribriform component and ADC 
without a cribriform component with respect to the expression 
of TTF-1, napsin, and CK7 evaluated in a previous study14 
(data available in at least 472 cases per marker), no significant 
differences were observed (data not shown).
Mutation data for KRAS, EGFR, BRAF, ALK, and 
ROS1 were available from previous studies16,17 for 410 cases 
of which 18 fell in the cribriform predominant category. 
Interestingly, cpADC did neither show somatic mutations 
in EGFR nor ROS1 or ALK translocations (p = 0.001). In 
contrast, however, the cribriform pattern featured the high-
est rate of somatic KRAS mutations of all growth patterns 
(p = 0.097). In addition, one of the 18 cpADC harbored a somatic 
BRAF mutation (Fig. 2, Supplementary Table 1, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A799).
TABLE 1.  Clinicopathological Correlations for the Cribriform 
Growth Pattern
Overall
No. of Cribriform 
Predominant Cases p Value
674 (100%) 28 (4.2%)
Age
  Below median 333 (49.4%) 17 (5.1%) 0.250
  Above median 341 (50.6%) 11 (3.2%)
Sex
  Male 392 (58.2%) 19 (4.8%) 0.332
  Female 282 (41.8%) 9 (3.2%)
pT
  1 138 (20.5%) 4 (2.9%) 0.265
  2 406 (60.2%) 18 (4.4%)
  3 102 (15.1%) 3 (2.9%)
  4 28 (4.2%) 3 (10.7%)
pN
  0 357 (53%) 11 (3.1%) 0.658
  1 111 (16.5%) 10 (9%)
  2 201 (29.8%) 7 (3.5%)
  3 5 (0.7%) 0 (0%)
pM
  0 652 (96.7%) 26 (4%) 0.231
  1 22 (3.3%) 2 (9.1%)
Stage
  1 264 (39.2%) 7 (2.7%) 0.214
  2 145 (21.5%) 9 (6.2%)
  3 243 (36.1%) 10 (4.1%)
  4 22 (3.2%) 2 (9.1%)
Smoking
  Nonsmoker 33 (9.2%) 1 (3%) 1.000
  Current or ex-
smoker
324 (90.8%) 13 (4%)
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Prognostic Impact of the Cribriform Pattern
Semiquantitative pattern analysis was a strong predictor 
of patient survival, regardless whether cribriform growth was 
included as an independent category (Table 2, Fig. 3) or not. 
With respect to OS, cpADC (mean OS: 62.7 months) ranged 
in between acinar (mean OS: 71.3 months) and solid predomi-
nant ADC (mean OS: 54.5 months; Fig. 3). This was also mir-
rored by a slight but nonsignificant negative shift in prognosis 
for acinar predominant ADC with a minor cribriform com-
ponent and a slight positive shift for solid predominant ADC 
with a minor cribriform component (Supplementary Figure 1, 
Supplemental Digital Content 2, http://links.lww.com/JTO/
A800). However, cpADC were associated with the worst DFS 
of all patterns (mean DFS: 36.9 months compared, e.g., with 
mean DFS for solid predominant ADC: 51.0 months; Fig. 3, 
Table 2).
In multivariate analyses, predominant pattern (including 
cribriform) was a stage-, age-, and sex-independent OS predic-
tor (p = 0.009, Supplementary Table 2, Supplemental Digital 
Content 3, http://links.lww.com/JTO/A801). The hazard ratio 
(HR) for the cribriform pattern was intermediate in this context 
with an HR of 1.72 (with lepidic set as the reference HR: 1), 
which was near the HR of acinar growth (HR: 1.75) but consid-
erably lower than the HR of solid growth (HR: 2.87). As could 
be expected from the data in univariate analysis, we observed 
a different association for cribriform growth with DFS, when 
multivariate analysis under inclusion of age, sex, stage, and 
predominant pattern was performed (Supplementary Table 3, 
Supplemental Digital Content 4, http://links.lww.com/JTO/
A802). Predominant pattern (p = 0.008) was an independent 
survival predictor. Like in univariate analyses, patients with a 
cpADC clearly had the worst DFS of all patterns with an HR 
of 2.99, which surpassed even the second worst HR of 2.05 
observed for patients with solid predominant ADC (reference 
was lepidic with an HR: 1).
DISCUSSION
In a series of 674 resected ADC, we here show that 
predominant cribriform ADC are rare. The presence of a 
minor cribriform component is associated with solid and aci-
nar growth. We observed high rates of KRAS and no EGFR 
mutations and demonstrated that patients with cpADC have 
a distinctively poor DFS. We could validate and extend the 
characterization of this specific ADC subtype and supply fur-
ther arguments for an inclusion of this pattern as a specific 
category into future classifications succeeding the upcoming 
2015 World Health Organization classification.18,19
With a 4.2% rate of cpADC and a minor cribriform pat-
tern in 28.6% of ADC cases, our results are in accordance with 
data from a previous study by Kadota et al11 who observed a 
rate of 4% for cpADC in a series of 1038 stage I cases and 
minor cribriform pattern in 25% of these cases and are also 
in-line with the study results from Moreira and colleagues20 
who described a rate of 5% predominant cribriform cases and 
a minor cribriform pattern in 15% of 249 analyzed stage I 
ADC. Interestingly, a third study reported cpADC in 34 of 125 
(27%) analyzed cases. In this study, cribriform ADC were sig-
nificantly more likely to demonstrate lymph node metastases 
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FIGURE 2.  Association of cribri-
form growth with other patterns. 
A, Distribution of a minor cribri-
form component within noncrib-
riform predominant patterns. B, 
Associations of the predominant 
growth pattern with proliferative 
activity (Ki-67). C, Association of 
the predominant growth pattern 
with molecular alterations of pul-
monary adenocarcinoma.
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compared with acinar predominant ADC and had a higher 
mitotic rate, rate of necrosis, vascular invasion, and prominent 
nucleoli.10 An association of the cribriform pattern with lym-
phovascular invasion and high mitotic activity was recently 
corroborated by an independent study.21 With respect to prolif-
eration, this fits with our data, where cribriform predominant 
tumors, after solid predominant ADC, had the second highest 
proliferation rate of all patterns.
At first glance, it is surprising that there are consider-
able differences for the number of predominant cases between 
the evaluation with inclusion of the cribriform pattern and the 
evaluation without inclusion of the cribriform pattern when 
there are only 28 cribriform predominant cases in the whole 
cohort (Table 2). According to the current IASLC/ATS/ERS 
classification, per definition the percentage of cribriform 
growth has to be added to acinar growth. This not only applies 
to the cases with a predominant cribriform pattern but also to 
cases with minor cribriform patterns. In all these cases, the 
percentages for cribriform growth have to be added to the 
acinar percentages, which results in a widespread increase in 
the percentages of acinar growth in a considerable fraction of 
cases. This, in some instances, means that acinar percentages 
TABLE 2.  Survival Associations for Clinicopathological Factors including the Cribriform Growth Pattern
Overall Mean Overall Survival (SE) p Value
Mean Disease-Free  
Survival (SE) p Value
674 64.9 (2.1) 56.9 (2.2)
Age
  Below median 333 67.7 (2.9) 0.353 53.0 (3.0) 0.057
  Above median 341 61.1 (3.0) 60.3 (3.2)
Sex
  Male 392 59.6 (2.6) <0.001 51.6 (2.7) 0.006
  Female 282 71.8 (3.4) 64.2 (3.5)
pT
  1 138 83.4 (4.2) <0.001 73.4 (4.7) <0.001
  2 406 63.4 (2.6) 55.1 (2.7)
  3 102 53.2 (5.0) 41.5 (5.4)
  4 28 37.3 (8.5) 23.2 (3.6)
pN
  0 357 80.4 (2.7) <0.001 71.3 (2.8) <0.001
  1 111 52.4 (4.6) 46.7 (5.1)
  2 201 42.5 (3.6) 30.7 (2.9)
  3 5 24.5 (4.6) 18.5 (5.4)
pM
  0 652 65.5 (2.1) 0.046 57.4 (2.2) 0.046
  1 22 28.1 (3.2) 22.6 (4.0)
Stage
  1 264 85.0 (2.9) <0.001 77.0 (3.0) <0.001
  2 145 62.4 (4.2) 53.2 (4.5)
  3 243 43.9 (3.3) 34.4 (3.2)
  4 22 28.1 (3.2) 22.6 (4.0)
Predominant pattern (with  
 cribriform)
  Cribriform 28 62.7 (8.6) <0.001 36.9 (8.4) <0.001
  Acinar 207 71.3 (3.7) 61.6 (3.9)
  Solid 248 54.5 (3.3) 50.5 (3.6)
  Papillary 101 55.9 (4.0) 49.6 (4.3)
  Micropapillary 55 67.6 (6.9) 56.8 (6.9)
  Lepidic 35 84.1 (5.2) 80.4 (5.5)
Predominant pattern (without 
 cribriform)
  Acinar 264 70.1 (3.2) <0.001 57.7 (3.5) <0.001
  Solid 226 53.2 (3.4) 51.0 (3.7)
  Papillary 95 56.1 (4.1) 48.6 (4.3)
  Micropapillary 54 68.6 (7.0) 57.7 (7.0)
  Lepidic 35 84.1 85.2) 80.4 (5.5)
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might become higher than percentages for the next frequent 
pattern when the percentages were already close in the first 
place. Such a shift in pattern frequencies, in turn, results in 
the formal reclassification of a considerable fraction of cases 
as acinar predominant ADC.
Of their 37 cases with cribriform pattern, Moreira et al20 
described 2 cases (5%) with EGFR mutations and 10 (27%) 
with KRAS mutations. Others described no specific molecu-
lar signature for cpADC but found the cribriform pattern 
predominantly in elderly patients with a smoking history and 
expression of TTF-1 and CK7.22 The latter two associations 
could not be confirmed in our data set. Kadota et al11 also did 
not find a correlation of cpADC with ALK expression, EGFR 
or KRAS mutations. Because the fraction of cribriform pre-
dominant cases is small in all series, further data are required 
to settle the question whether specific associations of molecu-
lar signatures with cribriform growth exist.
Maeshima and colleagues23 provided first evidence 
that the cribriform pattern is associated with a poor survival, 
which was recently confirmed by others.10,11,20 The recurrence-
free probability for patients with cpADC was significantly 
lower than that for patients with acinar or papillary predomi-
nant ADC but was comparable with that for patients with 
micropapillary or solid predominant ADC.11 Here, we could 
specifically demonstrate that cpADC have the worst outcome 
for DFS among all patterns, suggesting that cribriform pattern 
might be rather grouped in the high-grade tumors together 
with solid and micropapillary predominant ADC and not into 
the acinar group as currently suggested.1 However, OS of 
patients with cpADC was intermediate and ranged in between 
survival of patients with acinar and solid predominant ADC. 
We can only speculate on the reasons for the differences 
between OS and DFS for cpADC. One explanation might be 
that the natural course of cpADC is quite aggressive (early 
disease recurrence) but that these tumors might respond bet-
ter to chemotherapy administered after relapse than some of 
the other patterns. However, this must clearly be validated in 
future studies.
Taken together, we could substantiate data on the dis-
tribution, molecular makeup, and the prognostic value of the 
cribriform pattern in pulmonary ADC. Our data argue in favor 
of an inclusion of the cribriform pattern as a specific category 
into future pulmonary ADC classification systems, which 
should be further validated in international cohorts.
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